Brief: Aura Biosciences Presents Final Phase 1B/2 Data For Its First Virus-Like Drug Conjugate, Au-011, In Patients With Choroidal Melanoma At The American Academy Of Ophthalmology 2021 Annual Meeting

Aura Biosciences

15/11/2021 16:01

Aura Biosciences Inc  AURA.O :
    * AURA BIOSCIENCES PRESENTS FINAL PHASE 1B/2 DATA FOR ITS
FIRST
VIRUS-LIKE DRUG CONJUGATE, AU-011, IN PATIENTS WITH CHOROIDAL
MELANOMA AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2021 ANNUAL
MEETING
    * AURA BIOSCIENCES INC - RESULTS AT 12 MONTHS SHOWED A
STATISTICALLY SIGNIFICANT REDUCTION IN TUMOR GROWTH RATE
    * AURA BIOSCIENCES INC - PRELIMINARY RESULTS INDICATE A
POSITIVE
SAFETY AND TOLERABILITY PROFILE FOR AU-011 VIA SC
ADMINISTRATION.

Source text for Eikon:  ID:nBw6GJmlJa 
Further company coverage:  AURA.O